DE69226835T2 - Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände - Google Patents

Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände

Info

Publication number
DE69226835T2
DE69226835T2 DE69226835T DE69226835T DE69226835T2 DE 69226835 T2 DE69226835 T2 DE 69226835T2 DE 69226835 T DE69226835 T DE 69226835T DE 69226835 T DE69226835 T DE 69226835T DE 69226835 T2 DE69226835 T2 DE 69226835T2
Authority
DE
Germany
Prior art keywords
methods
compositions
hypoglycaemia
diseases
diabetes mellitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69226835T
Other languages
English (en)
Other versions
DE69226835D1 (de
Inventor
Kevin Beaumont
Andrew Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/670,231 external-priority patent/US5264372A/en
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69226835D1 publication Critical patent/DE69226835D1/de
Publication of DE69226835T2 publication Critical patent/DE69226835T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69226835T 1991-03-15 1992-03-13 Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände Expired - Fee Related DE69226835T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/670,231 US5264372A (en) 1991-03-15 1991-03-15 Receptor-based screening methods for amylin agonists and antagonists
US70499591A 1991-05-24 1991-05-24
US07/774,411 US5321008A (en) 1991-01-10 1991-10-10 Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
PCT/US1992/002191 WO1992016222A1 (en) 1991-03-15 1992-03-13 Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions

Publications (2)

Publication Number Publication Date
DE69226835D1 DE69226835D1 (de) 1998-10-08
DE69226835T2 true DE69226835T2 (de) 1999-01-14

Family

ID=27418205

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69226835T Expired - Fee Related DE69226835T2 (de) 1991-03-15 1992-03-13 Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände

Country Status (11)

Country Link
US (2) US5321008A (de)
EP (1) EP0533898B1 (de)
JP (1) JPH05507943A (de)
AT (1) ATE170401T1 (de)
AU (1) AU648895B2 (de)
CA (1) CA2082928C (de)
DE (1) DE69226835T2 (de)
DK (1) DK0533898T3 (de)
ES (1) ES2122995T3 (de)
MX (1) MX9201110A (de)
WO (1) WO1992016222A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0525149T3 (da) * 1991-01-10 1997-12-01 Amylin Pharmaceuticals Inc Amylinaktivitetsassays
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
US6143718A (en) 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
EP1044015B1 (de) * 1998-01-09 2008-10-08 Amylin Pharmaceuticals, Inc. Formulierungen für amylin peptidagonisten mit insulin
US6936584B1 (en) 1998-02-13 2005-08-30 Amylin Pharmaceuticals, Inc. Mixed amylin activity compounds
EP1053001B1 (de) 1998-02-13 2010-12-15 Amylin Pharmaceuticals, Inc. Neue verbindungen mit gemischter amylin aktivität
EP2085109A3 (de) * 2000-10-26 2009-09-02 Alza Corporation Transdermale Arzneimittelverabreichungsvorrichtungen mit beschichteten Mikrovorsprüngen
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
NZ541365A (en) * 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
AU2005260025A1 (en) * 2004-06-29 2006-01-12 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20110152183A1 (en) * 2008-06-25 2011-06-23 Novo Nordisk A/S Derivatised hybrid peptides of amylin and salmon calcitonin
NZ595021A (en) * 2009-03-12 2013-04-26 Nordic Bioscience As Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists
CN117653715A (zh) * 2017-02-03 2024-03-08 范德比尔特大学 用于治疗糖尿病的系统、组合物和方法
JP2022504596A (ja) 2018-10-11 2022-01-13 インターシア セラピューティクス，インコーポレイティド ヒトアミリンアナログペプチド及び使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037943B1 (de) * 1980-03-31 1985-08-14 Teijin Limited Pharmazeutische Zusammensetzung zur rektalen Verabreichung und daraus hergestellte Zäpfchen
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
EP0348490B1 (de) * 1988-01-11 1995-09-27 Amylin Pharmaceuticals, Inc. Behandlung von diabetes mellitus typ 2
NZ234428A (en) * 1989-07-10 1997-08-22 Amylin Corp Use of an amylin antagonist in the treatment of obesity and essential hypertension

Also Published As

Publication number Publication date
US5321008A (en) 1994-06-14
CA2082928C (en) 2000-09-05
EP0533898A4 (en) 1993-10-13
JPH05507943A (ja) 1993-11-11
ES2122995T3 (es) 1999-01-01
EP0533898A1 (de) 1993-03-31
AU1687392A (en) 1992-10-21
AU648895B2 (en) 1994-05-05
DE69226835D1 (de) 1998-10-08
ATE170401T1 (de) 1998-09-15
CA2082928A1 (en) 1992-09-16
DK0533898T3 (da) 1999-05-31
WO1992016222A1 (en) 1992-10-01
EP0533898B1 (de) 1998-09-02
US5508260A (en) 1996-04-16
MX9201110A (es) 1993-07-01

Similar Documents

Publication Publication Date Title
DE69226835D1 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände
ATE194918T1 (de) Behandlung von diabetes
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE271406T1 (de) Chrom enthaltende zusammensetzung zur behandlung von diabetes, zur verbesserung der insulinsensitivität und zur reduktion von hyperglykämie, hypercholesterolämie und des körperfettanteils
NO940180D0 (no) Anvendelse av IGF-I
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
RU95108231A (ru) Glp-1-молекулярный комплекс, фармацевтическая композиция и способ получения комплекса
DE69940975D1 (de) Verwendung von glp-1 oder analoge zur behandlung von schlaganfall
EA200000041A1 (ru) Способ лечения диабета тиазолидиндионом и метформином
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
DE69100282T3 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE69841279D1 (de) Verwendung von humanem Parathyroid-hormon
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
ATE192656T1 (de) Verfahren zur behandlung von patienten mit chronischer lebererkrankung
DE69305091D1 (de) Methode zur behandlung oder verhütung von fettleibigkeit
DE69728654D1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
ATE501760T1 (de) E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen
DE69803298T2 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
ATE197764T1 (de) Zusammensetzung zur behandlung des insulinmangels bei säugetieren, die amylin und insulin enthält.
ATE484293T1 (de) Verfahren zur vorbeugung oder behandlung von diabetes
UA35855A (uk) Спосіб лікування пилового бронхіту

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee